share_log

Roche Huntington-Disease Trial Halt Seen as Setback to Sentiment -- Market Talk

Roche Huntington-Disease Trial Halt Seen as Setback to Sentiment -- Market Talk

羅氏亨廷頓-疾病試驗暫停被視為人氣受挫-市場談話
Dow Jones Newswires ·  2021/03/23 16:49

DJ Roche Huntington-Disease Trial Halt Seen as Setback to Sentiment -- Market Talk

DJ羅氏亨廷頓-疾病試驗暫停被視為情緒受挫-市場談話

0849 GMT - The halt to Roche's phase-3 trial of Huntington-disease drug tominersen is presumably because the drug has insufficient efficacy, Jefferies says. Given the fact that tominersen was widely wiewed to be a significant blockbuster option in the Swiss major's pipeline, this news is a setback to sentiment, according to Jefferies. The drug had potential as a blockbuster asset, considering that no therapies are currently approved to slow the progression of the disease, Jefferies says.The investment bank reiterates its hold recommendation on Roche's stock. Roche trades down 1.8% at CHF309.35. (cecilia.butini@wsj.com)

0849GMT-傑弗瑞説,羅氏暫停亨廷頓病藥物Tominesen的3期試驗大概是因為該藥物療效不足。傑富瑞表示,鑑於托馬納森被廣泛認為是這位瑞士少校未來的重要重磅炸彈選擇,這一消息對市場人氣來説是一個挫折。Jefferies説,考慮到目前還沒有批准任何延緩疾病進展的療法,這種藥物有潛力成為一項重磅資產。這家投資銀行重申了對羅氏股票的持有建議。羅氏股價下跌1.8%,至309.35瑞士法郎。(cecilia.butini@wsj.com)

(END) Dow Jones Newswires

(完)道瓊通訊社

March 23, 2021 04:49 ET (08:49 GMT)

美國東部時間2021年3月23日04:49(格林尼治標準時間08:49)

Copyright (c) 2021 Dow Jones & Company, Inc.

版權所有(C)2021年道瓊斯公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論